Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

2010 ◽  
Vol 21 (1) ◽  
pp. 5-13 ◽  
Author(s):  
Laurent Ducry ◽  
Bernhard Stump
Keyword(s):  
Monoclonal Antibodies ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples

2021 ◽  
pp. 329-350
Author(s):  
Sophia N. Karagiannis ◽  
Ricarda M. Hoffmann ◽  
Mano Nakamura ◽  
Silvia Crescioli ◽  
Heather J. Bax ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

scholarly journals Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma

Cancers ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 15 ◽  
Author(s):  
Francesca Bonello ◽  
Roberto Mina ◽  
Mario Boccadoro ◽  
Francesca Gay
Keyword(s):  
Multiple Myeloma ◽  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
T Cell ◽  
Plasma Cells ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Promising Target ◽  
Therapeutic Monoclonal Antibodies ◽  
Antibody Drug

Immunotherapy is the latest innovation for the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) entered the clinical practice and are under evaluation in clinical trials. MAbs can target highly selective and specific antigens on the cell surface of MM cells causing cell death (CD38 and CS1), convey specific cytotoxic drugs (antibody-drug conjugates), remove the breaks of the immune system (programmed death 1 (PD-1) and PD-ligand 1/2 (L1/L2) axis), or boost it against myeloma cells (bi-specific mAbs and T cell engagers). Two mAbs have been approved for the treatment of MM: the anti-CD38 daratumumab for newly-diagnosed and relapsed/refractory patients and the anti-CS1 elotuzumab in the relapse setting. These compounds are under investigation in clinical trials to explore their synergy with other anti-MM regimens, both in the front-line and relapse settings. Other antibodies targeting various antigens are under evaluation. B cell maturation antigens (BCMAs), selectively expressed on plasma cells, emerged as a promising target and several compounds targeting it have been developed. Encouraging results have been reported with antibody drug conjugates (e.g., GSK2857916) and bispecific T cell engagers (BiTEs®), including AMG420, which re-directs T cell-mediated cytotoxicity against MM cells. Here, we present an overview on mAbs currently approved for the treatment of MM and promising compounds under investigation.

scholarly journals Native and Denaturing MS Protein Deconvolution for Biopharma: Monoclonal Antibodies and Antibody–Drug Conjugates to Polydisperse Membrane Proteins and Beyond

2019 ◽  
Vol 91 (15) ◽  
pp. 9472-9480 ◽  
Author(s):  
Iain D. G. Campuzano ◽  
John H. Robinson ◽  
John O. Hui ◽  
Stone D.-H. Shi ◽  
Chawita Netirojjanakul ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Membrane Proteins ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

scholarly journals Antibody–drug conjugates as novel anti-cancer chemotherapeutics

2015 ◽  
Vol 35 (4) ◽  
Author(s):  
Christina Peters ◽  
Stuart Brown
Keyword(s):  
Monoclonal Antibodies ◽  
Small Molecule ◽  
Current Knowledge ◽  
Cytotoxic Agent ◽  
Cancer Drugs ◽  
Antibody Drug Conjugates ◽  
Cancer Chemotherapeutics ◽  
Drug Conjugates ◽  
Anti Cancer ◽  
Antibody Drug

Antibody drug conjugates (ADCs) are an efficacious class of anti-cancer drugs that comprise monoclonal antibodies (mAbs) conjugated to small-molecule cytotoxic agent via a stable linker. This review summarizes the current knowledge and developments in the field of ADCs.

Monoclonal antibodies, small molecule inhibitors and antibody-drug conjugates as HER2 inhibitors

2020 ◽  
Vol 27 ◽  
Author(s):  
Xiu-Fang Li ◽  
Chen-Fu Liu ◽  
Guo-Wu Rao
Keyword(s):  
Monoclonal Antibodies ◽  
Small Molecule ◽  
Small Molecule Inhibitors ◽  
Growth Factor Receptor ◽  
Research Progress ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Her 2 ◽  
Epidermal Growth ◽  
Antibody Drug

: Overexpression of human epidermal growth factor receptor (HER)-2 is found in a variety of cancers, often portending poor clinical outcomes. Therefore, HER2 is an attractive target for treatment. This review describes the research progress of HER2 targeted inhibitors in recent years. Excellent reviews are available, so we focus on the development, mechanisms of action, and structure-activity relationships of different types of inhibitors, including monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates (ADCs). In addition, the differences among them are compared.

scholarly journals Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity

mAbs ◽  
2017 ◽  
Vol 9 (4) ◽  
pp. 615-627 ◽  
Author(s):  
Jillian M. Prendergast ◽  
Ana Paula Galvao da Silva ◽  
David A. Eavarone ◽  
Darius Ghaderi ◽  
Mai Zhang ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Tumor Specificity ◽  
Anti Tumor Activity ◽  
Sialyl Tn ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document